Scopio Labs, a developer of Full-Field Digital Cell Morphology™ imaging and analysis platforms, has achieved a milestone with the grant of De Novo clearance by the US Food and Drug Administration (FDA) for its Full-Field Bone Marrow Aspirate™ (FF-BMA) Application. 

This clearance establishes a new regulatory category for all-digital bone marrow aspirate analysis software, heralding a transformative era in hematologic diagnostics.

Bone marrow cytology, a cornerstone of diagnosing blood disorders, has historically relied on labor-intensive manual methods, often necessitating highly skilled hematopathologists for accuracy. With hematologic malignancies comprising approximately 10 percent of all diagnosed cancers in the US and remaining a significant global health concern, the demand for efficient and precise diagnostic solutions is paramount.

Scopio's FF-BMA Application revolutionizes bone marrow aspirate analysis by introducing a fully digital workflow that seamlessly integrates with its X100 and X100HT platforms. Through the fusion of high-resolution Full-Field imaging and an AI-powered decision support system (DSS), this innovative solution aims to empower healthcare professionals and enhance patient care.

Itai Hayut, CEO of Scopio Labs, commended the FDA for recognizing the critical need to support hematology experts and underscored the approval's significance in equipping labs with robust decision support systems. "The approval of the FF-BMA Application arms them with robust decision support systems. By harnessing AI and Full-Field imaging, labs can streamline workflows, reduce operational costs, and enhance patient care," said Hayut.

Adam Bagg, MD, a Professor of Pathology and Laboratory Medicine at the University of Pennsylvania and a lead investigator in the BMA study submitted to the FDA, emphasized the urgency for digital innovation amid the escalating prevalence of hematologic conditions. "By optimizing digital workflows and enabling unique remote review of entire smears, we are hopeful this technology can help enhance efficiency across the board," said Bagg.

The FF-BMA Application is tailored to streamline BMA review and reporting for trained operators. It automates the detection and visualization of hematopoietic cells in stained smears, facilitating critical evaluations such as bone marrow smear quality assessment, blast cell and plasma cell estimation, and the calculation of the myeloid to erythroid (M:E) ratio. This innovative tool aims to standardize BMA analysis, enhance diagnostic precision, and ultimately improve patient care.